Revvity ($RVTY) Stock Forecast: Up 5.1% Today

What is Revvity?

Revvity Inc. (RVTY) operates in the diagnostics and research sector, offering crucial drug development services. Recently, the company's stock showed significant upward momentum despite market volatility.

Why is Revvity going up?

RVTY stock is up 5.1% on Apr 24, 2026 17:36

• Revvity's stock price rose following the announcement of an anticipated fourth-quarter revenue of $772 million, in line with analyst predictions.
• While other companies in the sector, such as Charles River Laboratories International and MEDP, faced a downturn, Revvity defied the trend and witnessed a bullish trend.
• Investor response to Revvity's revenue forecasts suggests confidence in the company's growth potential despite challenges in the industry.
• The increase in Revvity's stock price may also be due to a reevaluation of the company's prospects amid sector-wide challenges, leading to greater institutional interest and changing investor sentiment.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Revvity expects to report Q4 revenue of $772 million

Revvity is projected to report fourth-quarter revenue of $772 million. This figure aligns with the consensus analyst estimate.

http://www.msn.com/en-us/money/companies/revvity-expects-to-report-q4-revenue-of-772-million/ar-AA1U81pQ?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t

Charles River Laboratories International Drops 7.2% Amid Sector-Wide Selling

Charles River Laboratories International (NYSE:CRL) saw its stock plunge by 7.2% to $171.57 due to a broad sector-wide selloff in the diagnostics and research industry. This decline was not attributed to company-specific issues but rather a synchronized downturn affecting multiple peers, with MEDP dropping 23.0% and RVTY falling 9.4%. The selling pattern suggests investors are re-positioning away from the sector, impacting CRL's valuation despite its essential drug development services.

https://news.alphastreet.com/charles-river-laboratories-international-drops-7-2-amid-sector-wide-selling/amp/

Revvity Inc. stock underperforms Thursday when compared to competitors

Revvity Inc. (RVTY) shares dropped by 7.56% on Thursday, closing at $87.15, underperforming the broader market. This decline occurred during a negative trading session where both the S&P 500 Index and the Dow Jones Industrial Average also experienced falls. The stock's downturn ended a two-day winning streak.

https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-thursday-when-compared-to-competitors-c37ac382-65c58ac74b66

Revvity Drops 10.0% Amid Sector-Wide Selling

Revvity, Inc. experienced a significant 10.0% drop in its stock price, closing at $84.88, as a broad selloff impacted the diagnostics and research sector. While the decline was not specific to Revvity, with several peers also falling, its drop was more pronounced than some, signaling potential reassessments of growth expectations or regulatory prospects across the industry. Elevated trading volume suggests institutional involvement, and investors are advised to monitor company statements, regulatory updates, and upcoming earnings reports to understand the underlying causes and future outlook.

https://news.alphastreet.com/revvity-drops-10-0-amid-sector-wide-selling/amp/

Revvity Drops 10.0% Amid Sector-Wide Selling

Revvity, Inc. (RVTY) saw a significant 10.0% drop in its stock price, closing at $84.88, due to a broad selloff affecting the diagnostics and research sector. This decline, which was not company-specific, impacted several peers with varying degrees of severity, indicating a potential reassessment of growth expectations or regulatory prospects across the industry. The elevated trading volume suggests institutional involvement in the selloff, highlighting shifting investment sentiment within the sector.

https://news.alphastreet.com/revvity-drops-10-0-amid-sector-wide-selling/

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Revvity Price History

12.01.2026 - RVTY Stock was down 7.6%

• Despite introducing new automation platforms, such as the Opera Phenix OptIQ system and EnVision Nexus One plate reader, at a recent industry event, Revvity's stock faced a bearish trend.
• The company's valuation being 27.4% below estimated fair value and a share price 15% below analyst targets might have contributed to the negative market movement.
• Investors are advised to closely monitor the adoption of these new platforms, their impact on revenue growth, and any adjustments to analyst forecasts to gauge the stock's future performance accurately.

12.01.2026 - RVTY Stock was down 5.2%

• Revvity's launch of innovative high-throughput discovery and automation platforms at SLAS2026 is intended to meet the need for quicker experiments and streamlined processes in labs, potentially driving recurring revenue.
• However, despite these advancements, the stock's downward trend may be attributed to concerns surrounding the company's diminishing 1, 3, and 5-year returns, alongside its valuation falling below projected fair value and analyst estimations.
• Investors' response to existing risks associated with Revvity, like its relatively high P/E ratio and highlighted concerns about one-time items impacting reported earnings, likely contributed to today's bearish market performance.

06.02.2026 - RVTY Stock was down 5.1%

• Revvity's stock exhibited a downward trend today, influenced by general market uncertainties and concerns regarding its capital allocation strategies.
• The unexpected decline in healthcare employment noted in the February jobs report has raised apprehensions about diminishing healthcare expenditure and demand, affecting companies in the healthcare sector like Revvity.
• Interrogations regarding Revvity's conservative 2026 outlook and capital allocation methods have prompted investors to reassess the company's prospects for growth, resulting in a downturn in the stock price.
• Despite the immediate hurdles, Revvity's strong array of products and ability to generate cash indicate that holding onto the stock in investment portfolios could be logical for long-term investors interested in its growth potential.

06.02.2026 - RVTY Stock was down 6.5%

• Revvity's stock has experienced bearish trends due to caution in the 2026 forecasts and investor apprehensions about capital allocation.
• Despite positive earnings and a promising FY2026 outlook, investor focus on capital management and its implications on future growth has overshadowed the company's strong fundamentals.
• Changes in Citigroup Inc.'s stake and increased institutional ownership indicate a mix of investor sentiments toward Revvity, contributing to the downward movement in stock value.
• The downward trajectory in Revvity's stock price today is attributed to market uncertainties regarding the company's capital allocation strategy and its potential impact on growth, shaping the prevailing bearish sentiment.

03.01.2026 - RVTY Stock was down 5.3%

• An analyst raised Revvity's price target to $124 from $120, reflecting a 15% premium over the current share price, but the stock saw a pre-market decline, possibly leading to profit-taking by investors.
• Despite positive momentum indicators and analyst upgrades, including from another firm, the market movement could be influenced by broader market trends or sector-specific challenges impacting investor sentiment.
• The strong Q4 results and optimistic fiscal 2026 outlook may have already been priced into the stock, leading to a sell-off after the earnings announcement as investors locked in gains.
• Overall, the bearish movement in Revvity's stock today could be a result of a combination of profit-taking, market dynamics, and potential overvaluation following the recent price target upgrades and positive analyst forecasts.

23.03.2026 - RVTY Stock was down 10.0%

• Today's decrease in Revvity Inc. (RVTY) stock price is linked to a widespread selloff in the diagnostics and research industry, affecting other companies like Charles River Laboratories International and MEDP.
• The Vice President of Revvity selling 80 shares through a pre-planned trading scheme may have influenced the negative market sentiment towards the stock.
• Despite the general market downturn, Revvity Inc. demonstrated better performance than its industry counterparts, reflecting resilience in the market.
• Investors could be exercising caution due to uncertainties in the sector, notwithstanding Revvity's strong market position, healthy free cash flow, and positive analyst projections.

23.03.2026 - RVTY Stock was down 7.6%

• The Vice President of Revvity, Anita Gonzales, conducted the sale of 80 shares through a pre-arranged trading plan, potentially indicating concerns about the company's short-term performance and contributing to the stock's decline.
• Despite Revvity's stock outperforming rivals on a challenging trading day in the recent past, the sale of shares by a key executive has raised investor apprehensions.
• The disclosure of selling 80 common shares by Revvity via a Form 144 notice, linked to an ESPP purchase and restricted stock vesting, may have exerted selling pressure on the stock and influenced its bearish movement.
• Analysts maintain a favorable outlook on Revvity's robust positioning and growth prospects within the healthcare R&D industry, offering potential support amid the prevailing bearish sentiment. However, the recent insider selling activity could be overshadowing this positive sentiment.

17.03.2026 - RVTY Stock was up 5.0%

• The bullish movement in Revvity's stock today is linked to the positive reception of its integrated cancer research solutions unveiled at the AACR Annual Meeting 2026, demonstrating the company's dedication to enhancing oncology research and patient outcomes.
• Investor optimism and interest in the stock have been fueled by the anticipation surrounding Revvity's upcoming earnings report, notably following the introduction of Signals BioDesign, a cloud-native molecular cloning platform.
• Despite recent downgrades by Barclays to an "equal weight" rating, Revvity's impressive Q4 earnings performance and strong FY2026 guidance have reinforced confidence in the company's growth prospects, contributing to the positive market movement observed today.

04.02.2026 - RVTY Stock was up 5.3%

• The positive performance of Revvity Inc. ($RVTY) today is correlated with its robust quarterly earnings results and optimistic future guidance.
• Despite recent challenges in share price and competition, the encouraging earnings report and positive outlook have instilled confidence among investors, leading to an upward trend in the stock.
• The increased interest from notable institutional investors, like Mitsubishi UFJ Asset Management Co. Ltd., reflects confidence in Revvity's future, contributing to its stock price increase.
• Different methods of valuation present varying perspectives, with DCF models indicating undervaluation and P/E ratios suggesting overvaluation. This disparity may have caused some fluctuations, but investors continue to capitalize on the positive earnings momentum.

24.03.2026 - RVTY Stock was up 5.1%

• Revvity's stock price rose following the announcement of an anticipated fourth-quarter revenue of $772 million, in line with analyst predictions.
• While other companies in the sector, such as Charles River Laboratories International and MEDP, faced a downturn, Revvity defied the trend and witnessed a bullish trend.
• Investor response to Revvity's revenue forecasts suggests confidence in the company's growth potential despite challenges in the industry.
• The increase in Revvity's stock price may also be due to a reevaluation of the company's prospects amid sector-wide challenges, leading to greater institutional interest and changing investor sentiment.

14.03.2026 - RVTY Stock was up 5.0%

• Revvity was downgraded by Barclays from Overweight to Equalweight, accompanied by a lowered price target, signaling a more cautious stance on the stock's trajectory.
• Despite positive Q1 2026 earnings expectations and consistent outperformance relative to Wall Street predictions, apprehensions regarding new international trade policies have caused Revvity's stock to diminish in value over the past year.
• The launch of Signals BioDesign underscores Revvity's strategic initiative to enhance molecular cloning and R&D data processing, addressing crucial requirements in biologics research, which could fuel long-term expansion despite recent stock fluctuations.
• Price target modifications by financial entities like Goldman Sachs and TD Cowen, combined with Revvity's underperformance compared to broader market benchmarks, are factors contributing to the varied outlook on the company's stock performance.

12.02.2026 - RVTY Stock was down 5.2%

• A notable institution, Barclays PLC, decreased its stake in Revvity by 11.5%, potentially reflecting concerns about the company's future prospects and influencing the bearish market movement.
• Conversely, Neuberger Berman Group LLC notably augmented its holdings in Revvity, indicating varying sentiments among institutional investors about the stock's potential.
• Investor enthusiasm for Revvity may have been tempered by a Bretton Fund letter cautioning about the 2026 outlook and scrutinizing capital allocation, potentially contributing to the downward trend.
• The unexpected decline in nonfarm payroll jobs, affecting the healthcare sector and Revvity among others, intensified market uncertainty and contributed to the stock's overall decline.